Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments.
| Title: | Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments. |
|---|---|
| Authors: | Teleanu RI; Department of Neuroscience, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Pediatric Neurology Department, 'Dr. Victor Gomoiu' Clinical Children's Hospital, 022102 Bucharest, Romania.; Moldoveanu ET; Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Niculescu AG; Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Research Institute of the University of Bucharest-ICUB, University of Bucharest, 050657 Bucharest, Romania.; Predescu E; Department of Neuroscience, Psychiatry and Pediatric Psychiatry, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400658 Cluj-Napoca, Romania.; Clinical Emergency Hospital for Children Cluj-Napoca, Clinic of Pediatric Psychiatry, 400394 Cluj-Napoca, Romania.; Roza E; Department of Neuroscience, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Pediatric Neurology Department, 'Dr. Victor Gomoiu' Clinical Children's Hospital, 022102 Bucharest, Romania.; Tincu IF; Department of Paediatrics, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Pediatric Gastroenterology Department, 'Dr. Victor Gomoiu' Clinical Children Hospital, 030167 Bucharest, Romania.; Grumezescu AM; Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Research Institute of the University of Bucharest-ICUB, University of Bucharest, 050657 Bucharest, Romania.; Teleanu DM; Department of Neuroscience, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. |
| Source: | Pharmaceutics [Pharmaceutics] 2025 May 28; Vol. 17 (6). Date of Electronic Publication: 2025 May 28. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI |
| Abstract: | The intestine is an important segment of the gastrointestinal tract, which is involved in complex processes that maintain the body's normal homeostasis. It hosts a vast, diverse, and dynamic microbial community called the gut microbiota, which develops from birth. It has been observed that the gut microbiota is involved in essential physiological processes, including the development of the central nervous system via the gut microbiota-brain axis. An alteration of the gut microbiota can lead to serious health problems, including defective neurodevelopment. Thus, this paper aims to highlight the most recent advances in studies that focus on the link between the gut microbiota and the evolution of neurodevelopmental diseases in children. Currently, studies show that the use of drugs that stimulate and restore the gut microbiota (e.g., probiotics and prebiotics) have the potential to alleviate some of the symptoms associated with conditions such as Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Tic Disorder, Tourette Syndrome, epilepsy, and Down Syndrome. In addition, due to the challenges associated with drug administration in children, as well as the widespread shortage of medications intended for pediatric use, researchers are working on the development of new delivery systems. Liposome-based systems or solid lipid nanoparticles have been safely used for drug delivery in various pediatric conditions, which may also indicate their potential for use in the administration of microbiota-modulating therapies. |
| References: | Drug Deliv Transl Res. 2021 Apr;11(2):471-497. (PMID: 33528830); BMC Nutr. 2021 Sep 8;7(1):48. (PMID: 34493339); Epilepsia. 2014 Apr;55(4):475-82. (PMID: 24730690); PLoS One. 2019 Jan 9;14(1):e0210064. (PMID: 30625189); J Control Release. 2021 Jul 10;335:457-464. (PMID: 34048841); Sci Rep. 2024 Feb 19;14(1):4037. (PMID: 38369656); Nutrients. 2021 Aug 08;13(8):. (PMID: 34444887); Neurosci Biobehav Rev. 2019 Dec;107:750-764. (PMID: 31626816); Front Pediatr. 2023 Nov 16;11:1252035. (PMID: 38034825); iScience. 2022 Oct 09;25(11):105313. (PMID: 36339270); Life (Basel). 2024 May 24;14(6):. (PMID: 38929656); Int J Pharm. 2022 Sep 25;625:122107. (PMID: 35964828); EBioMedicine. 2022 Mar;77:103908. (PMID: 35255456); Front Nutr. 2021 May 10;8:644138. (PMID: 34041257); Microbiologyopen. 2022 Feb;11(1):e1260. (PMID: 35212478); Front Nutr. 2022 Nov 16;9:1028459. (PMID: 36466385); Front Cell Infect Microbiol. 2022 Jul 22;12:915701. (PMID: 35937689); Nutrients. 2021 Jun 19;13(6):. (PMID: 34205336); Am J Med Sci. 2018 Nov;356(5):413-423. (PMID: 30384950); J Nanobiotechnology. 2022 Jun 7;20(1):262. (PMID: 35672712); J Affect Disord. 2023 Oct 15;339:860-866. (PMID: 37495084); Pharmacol Res. 2020 Jul;157:104784. (PMID: 32305492); Front Pediatr. 2021 Apr 22;9:652208. (PMID: 33968854); Br Med Bull. 2018 Sep 1;127(1):91-100. (PMID: 30215678); Integr Med (Encinitas). 2016 Mar;15(1):33-6. (PMID: 27053934); MMWR Surveill Summ. 2025 Apr 17;74(2):1-22. (PMID: 40232988); Microorganisms. 2023 Feb 15;11(2):. (PMID: 36838452); Eur Child Adolesc Psychiatry. 2022 Jan;31(1):189-202. (PMID: 33999314); J Appl Microbiol. 2020 Oct;129(4):787-805. (PMID: 32277534); EBioMedicine. 2021 Jul;69:103475. (PMID: 34256346); Front Microbiol. 2023 Jan 17;14:1098412. (PMID: 36733917); Int J Biol Macromol. 2024 Feb;258(Pt 1):128826. (PMID: 38123040); Eur J Nutr. 2018 Feb;57(1):1-24. (PMID: 28393285); Neurobiol Dis. 2022 Feb;163:105598. (PMID: 34942335); JAMA Neurol. 2018 Mar 1;75(3):279-286. (PMID: 29279892); Int J Pharm. 2021 May 15;601:120571. (PMID: 33812967); J Glob Health. 2021 Feb 11;11:04009. (PMID: 33692893); Expert Opin Drug Deliv. 2016 Aug;13(8):1121-31. (PMID: 27073977); Nutrients. 2021 Oct 21;13(11):. (PMID: 34835954); Int J Tryptophan Res. 2009 Mar 23;2:45-60. (PMID: 20651948); Microorganisms. 2019 Jan 10;7(1):. (PMID: 30634578); Int J Mol Sci. 2022 May 25;23(11):. (PMID: 35682615); Front Cell Neurosci. 2017 Apr 28;11:120. (PMID: 28503135); Protein Cell. 2023 Oct 25;14(10):762-775. (PMID: 37166201); Expert Opin Pharmacother. 2016;17(7):937-52. (PMID: 26891879); Gastroenterology. 2021 Jan;160(2):495-506. (PMID: 33307032); Life (Basel). 2022 Jan 20;12(2):. (PMID: 35207440); Int J Mol Sci. 2024 Oct 07;25(19):. (PMID: 39409095); Nutrients. 2024 May 07;16(10):. (PMID: 38794639); Genome Med. 2020 Sep 28;12(1):82. (PMID: 32988391); Pediatr Res. 2019 Jan;85(2):216-224. (PMID: 30283047); J Child Neurol. 2020 Feb;35(2):166-174. (PMID: 31608744); Eur Child Adolesc Psychiatry. 2020 Mar;29(3):287-297. (PMID: 31119393); Biochem J. 2017 May 16;474(11):1823-1836. (PMID: 28512250); Nat Commun. 2019 Dec 19;10(1):5783. (PMID: 31857577); J Neurogastroenterol Motil. 2023 Jan 30;29(1):94-101. (PMID: 36606440); Front Mol Biosci. 2020 Oct 30;7:587997. (PMID: 33195435); Curr Oncol Rep. 2016 Jul;18(7):45. (PMID: 27255389); N Engl J Med. 2020 Jun 11;382(24):2344-2352. (PMID: 32521135); Front Cell Dev Biol. 2022 Apr 14;10:880544. (PMID: 35493075); Nat Rev Dis Primers. 2020 Jan 16;6(1):5. (PMID: 31949163); Nat Rev Dis Primers. 2020 Feb 6;6(1):9. (PMID: 32029743); Int J Mol Sci. 2020 Jul 02;21(13):. (PMID: 32630718); Dig Liver Dis. 2018 May;50(5):421-428. (PMID: 29567414); Molecules. 2018 Apr 14;23(4):. (PMID: 29662019); Int J Mol Sci. 2023 Nov 07;24(22):. (PMID: 38003224); Mol Psychiatry. 2019 Mar;24(3):390-408. (PMID: 29955166); Adv Nutr. 2025 Feb;16(2):100362. (PMID: 39733798); Front Cell Infect Microbiol. 2023 Oct 04;13:1282431. (PMID: 37868345); Nutrients. 2021 May 05;13(5):. (PMID: 34062986); Fac Rev. 2021 Sep 07;10:70. (PMID: 34557874); Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):428-440. (PMID: 37594208); Exp Physiol. 2024 May;109(5):662-671. (PMID: 38156734); Pharmaceutics. 2018 Oct 18;10(4):. (PMID: 30340327); Antioxidants (Basel). 2023 Mar 03;12(3):. (PMID: 36978881); Neurol Ther. 2025 Feb;14(1):279-290. (PMID: 39699746); World J Clin Pediatr. 2021 May 9;10(3):15-28. (PMID: 33972922); Adv Healthc Mater. 2023 Oct;12(25):e2300319. (PMID: 37384827); Nature. 2022 Apr;604(7907):732-739. (PMID: 35418674); Front Pediatr. 2022 Mar 07;10:815885. (PMID: 35321011); J Tradit Complement Med. 2022 Mar 08;13(2):135-149. (PMID: 36970459); Biomedicines. 2022 Aug 31;10(9):. (PMID: 36140237); PLoS One. 2023 Aug 18;18(8):e0273890. (PMID: 37594987); Molecules. 2021 Sep 10;26(18):. (PMID: 34576981); Pharmacol Res. 2013 Mar;69(1):127-36. (PMID: 23178557); Molecules. 2025 Mar 24;30(7):. (PMID: 40286039); Trends Microbiol. 2019 Dec;27(12):997-1010. (PMID: 31474424); Chembiochem. 2016 May 17;17(10):886-9. (PMID: 26919463); Microorganisms. 2020 Apr 07;8(4):. (PMID: 32272588); World J Clin Cases. 2019 Sep 6;7(17):2420-2426. (PMID: 31559278); Sci Rep. 2019 Jul 12;9(1):10128. (PMID: 31300667); Molecules. 2022 Feb 17;27(4):. (PMID: 35209162); World J Gastroenterol. 2022 May 14;28(18):1875-1901. (PMID: 35664966); Neurotherapeutics. 2022 Jan;19(1):248-262. (PMID: 35029811); Seizure. 2021 Aug;90:80-92. (PMID: 33762166); Pharm Dev Technol. 2022 Jun;27(5):525-544. (PMID: 35635506); Lancet Neurol. 2023 Feb;22(2):147-158. (PMID: 36354027); Sci Rep. 2022 Feb 4;12(1):1936. (PMID: 35121796); Front Immunol. 2017 Dec 20;8:1882. (PMID: 29326727); Clin Nutr. 2022 Aug;41(8):1680-1688. (PMID: 35777107); ACS Mater Au. 2023 Aug 21;3(6):600-619. (PMID: 38089666); Neurosci Biobehav Rev. 2023 Jun;149:105156. (PMID: 37019246); Heliyon. 2022 May 13;8(5):e09394. (PMID: 35600452); World J Gastroenterol. 2014 Nov 21;20(43):16079-94. (PMID: 25473159); Pharmaceutics. 2021 Jul 31;13(8):. (PMID: 34452143); EClinicalMedicine. 2024 Jan 23;68:102428. (PMID: 38312240); Res Pharm Sci. 2018 Aug;13(4):288-303. (PMID: 30065762); J Pediatr (Rio J). 2023 Jan-Feb;99(1):11-16. (PMID: 35914739); Biosci Microbiota Food Health. 2021;40(1):12-18. (PMID: 33520564); Children (Basel). 2024 Jun 28;11(7):. (PMID: 39062245); RSC Adv. 2020 Jul 17;10(45):26777-26791. (PMID: 35515778); Nutrients. 2024 Jun 21;16(13):. (PMID: 38999736); Front Cell Neurosci. 2017 Feb 07;11:25. (PMID: 28223922); Pediatrics. 2014 Aug;134(2):361-72. (PMID: 25022739); Gut Microbes. 2025 Dec;17(1):2463570. (PMID: 39963956); Front Neurol. 2019 Jul 30;10:727. (PMID: 31417479); Neuropsychiatr Dis Treat. 2021 Apr 30;17:1253-1266. (PMID: 33958867); Annu Rev Pharmacol Toxicol. 2014;54:559-80. (PMID: 24160697); Pharmaceutics. 2021 May 07;13(5):. (PMID: 34066953); Children (Basel). 2022 Apr 01;9(4):. (PMID: 35455532); Nutrients. 2024 Jul 13;16(14):. (PMID: 39064703); Neuropharmacology. 2023 Jun 15;231:109491. (PMID: 36924923); Mol Pharm. 2017 Jun 5;14(6):1969-1979. (PMID: 28460165); Neuropediatrics. 2020 Oct;51(5):315-335. (PMID: 32559806) |
| Contributed Indexing: | Keywords: children neurodevelopmental disorders; gut microbiota; liposomal drug delivery systems; prebiotics; probiotics; solid lipid nanoparticles |
| Entry Date(s): | Date Created: 20250627 Latest Revision: 20250629 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12195671 |
| DOI: | 10.3390/pharmaceutics17060707 |
| PMID: | 40574020 |
| Database: | MEDLINE |
Journal Article; Review